Effects of *Lactobacillus coryniformis* K8 CECT5711 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial

Juristo Fonollá1 · Carlos Gracián2,3,4 · Jose A. Maldonado-Lobón1 · Carlos Romero5 · Alicia Bédmar6 · Juan C. Carrillo3 · Carmen Martín-Castro3 · Antonio L. Cabrera3 · Jose M. García-Curiel4 · Carlos Rodríguez1 · Sara Sanbonmatsu7 · Mercedes Pérez-Ruiz7 · Jose M. Navarro7 · Mónica Olivares1

Received: 19 June 2017 / Accepted: 27 October 2017 / Published online: 9 November 2017 © The Author(s) 2017. This article is an open access publication

Abstract

**Purpose** Elderly people are particularly vulnerable to seasonal influenza. Therefore, vaccination is strongly recommended. However, the vaccine efficacy is lower in the elderly, owing to immunosenescence. The objective of the present study was to evaluate the ability of the probiotic strain *Lactobacillus coryniformis* K8 CECT5711 to enhance the immune response to the influenza vaccine in the elderly and to assess the effects on symptoms related to respiratory infections.

**Methods** A randomized, double-blind, placebo-controlled trial was conducted between November 2015 and April 2016. A total of 98 nursing home residents, more than 65 years of age were randomly assigned to receive *L. coryniformis* K8 CECT5711 (3 × 10⁹ CFU/day) or a placebo for 2 weeks before influenza vaccination. The primary outcome was the percentage of seroconversion. The secondary outcomes were the incidence of influenza-like illness (ILI) and respiratory symptoms associated with respiratory infections during the 5-month follow-up period. The serum cytokine and immunoglobulin levels were also evaluated.

**Results** The percentage of responders to vaccination was higher in the probiotic group than in the control group (*p* = 0.036). *L. coryniformis* ingestion was associated with a significantly lower incidence of respiratory symptoms commonly associated with respiratory infections (*p* = 0.007) and lower consumption of analgesics (*p* = 0.008).

**Conclusion** The administration of *L. coryniformis* K8 CECT5711 to an elderly population increased the immune response against the influenza vaccine and decreased symptoms associated with respiratory infections. Probiotic administration may be a natural and safe strategy to improve the efficacy of vaccines and to protect against common respiratory infections in susceptible populations.

**Keywords** Antiviral immunity · Immunomodulation · Probiotic · Respiratory viruses · Vaccine

Introduction

The influenza A and B viruses are important human respiratory pathogens. Influenza occurs globally with an annual attack rate estimated at 5–10% in adults and 20–30% in children [1]. The elderly are particularly vulnerable to seasonal influenza; indeed, approximately 90% of all influenza-related deaths occur among senior citizens [2]. Vaccination remains the most effective public health measure to decrease the effect of seasonal influenza and is strongly recommended for this population [1]. However, the efficacy of the vaccine is lower in the elderly, owing to the immunosenescence characteristic of this population [3, 4]. For this reason, the use of adjuvants has been proposed to enhance the immune response to the influenza vaccine in the elderly. However,
the injection of the adjuvant together with the vaccine can increase the incidence of undesirable local or systemic responses [5].

The Lactobacillus genus is a common inhabitant of the human gut. Interactions between some representatives of this bacterial genus and the immune system have been demonstrated to enhance the immune response [6]. This activity would be involved in the preventive effect of certain probiotic strains on respiratory infections, as shown in different trials [7–11]. The ability of certain Lactobacillus strains to modulate the immune response has also been used to increase the response to vaccines by acting as adjuvants [12, 13]. The use of an oral probiotic administration strategy would avoid the adverse effects associated with the direct injection of chemical adjuvants.

Lactobacillus coryniformis K8 CECT5711 (Lc K8) is a strain originally isolated from an artisanal goat cheese [14]. This strain has been found to have immunomodulatory activity in a previous study in which fermented milk containing Lc K8 in combination with the strain L. gasseri CECT5711 was administered to healthy adults and enhanced both innate and specific immune responses [15]. Two additional studies performed in children with the same fermented milk containing the combination of Lactobacillus strains corroborated the effect on the immune system [16, 17]. Recently, oral administration of Lc K8 as a food supplement to healthy adults has been reported to increase specific antibodies against hepatitis A virus after a vaccination protocol [18]. The objective of the present study was to evaluate the ability of Lc K8 to enhance the immune response to the influenza vaccine in the elderly and to assess the effects on respiratory symptoms related to respiratory infections.

Materials and methods

Study design

A randomized double-blinded placebo-controlled multicentre trial was performed. The study was started in October 2015 and ended in April 2016.

Volunteers were recruited from five nursing homes in Granada (Spain) at the beginning of the vaccination programme. The inclusion criteria were nursing home residents more than 65 years of age. The exclusion criteria were frequent gastrointestinal diseases; antibiotic treatment during the intervention; allergy to any group of antibiotics, egg proteins or adjuvants; and excipients of the flu vaccine. The study was conducted according to the Declaration of Helsinki, and the protocol was approved by the Regional Ethical Committee (Granada, Spain). Informed consent was obtained from all subjects. The trial was registered in the US Library of Medicine (http://www.clinicaltrial.gov) under number NCT03167593.

The volunteers were randomly assigned to one of two groups according to a randomization scheme generated by a computer programme (SIGESMU®). The individuals in the placebo group consumed a capsule containing 300 mg of maltodextrin daily, whereas the individuals in the probiotic group consumed a capsule containing $3 \times 10^9$ colony forming units of strain L. coryniformis K8 CECT5711 (Lc K8) in a matrix of the same maltodextrin mixture, daily. The probiotic and placebo were provided in identical gelatin capsules packaged in identical plastic containers with a code number that referred to the volunteer code according to the randomization. The capsules were kept at 4 °C to maintain the stability of the viable bacteria concentration in the product. The consumption of any probiotic supplement was restricted from 2 weeks before the beginning of the intervention until the end of the study. During the 2 weeks before flu vaccination, the volunteers received a capsule of probiotic or placebo daily. On day 15 of the study, all volunteers received intramuscular vaccination against the flu. The vaccination was conducted by the medical services of the nursing homes with a vaccine containing inactivated trivalent influenza (A/California/7/2009[H1N1]pdm09, A/HongKong/4801/2014[H3N2], and B/Brisbane/60/2002) for the vaccine campaign of 2015/2016 (Sanofi Pasteur Europe, Lyon, France). All volunteers were vaccinated during the same week (second week of November 2015). After vaccination, the volunteers were followed up until 30 April 2016.

The sample size was estimated according to the effect on the main outcome of the study (seroconversion). On the basis of the expected level, the study was designed to exhibit sufficient power (80%) to detect a difference between groups of 30% in the proportion of seroconverters with a 0.05 significance level (R software version 2.12.2). The number of volunteers necessary was 43 per group, and the total sample size was increased to 100 volunteers to compensate for dropouts.

Study outcomes

The primary outcome of the study was the percentage of seroconversion. According to the European Centre for Disease Prevention and Control (ECDC), for a population older than 60 years of age, seroconversion corresponds to the proportion of vaccinated individuals achieving a haemagglutination inhibition (HAI) titre > 1:40 or a significant increase in the HAI antibody titre (i.e., at least a four-fold titre increase) [19].

The secondary outcome was the incidence of influenza-like illness (ILI) during the follow-up period. The ILI diagnosis was based on the case definition used by the European Centre for Disease Prevention and Control (as mandated by
the European Union for communicable disease reporting, is henceforth abbreviated EU-ECDC) as follows: sudden onset of symptoms with one or more respiratory symptoms (cough, sore throat and/or shortness of breath) plus one or more systemic symptoms (self-reported fever, headache, myalgia and/or malaise) [20].

Other outcomes were the levels of cytokines (IL-10, IL-4, and TNF-alpha), immunoglobulin A (IgA) and immunoglobulin G (IgG).

Gastrointestinal manifestations, such as nausea, vomiting and lack of appetite, and the consumption of analgesics and antibiotics during the follow-up period were also recorded.

All data about the health conditions of the volunteers and the consumption of medical treatments were evaluated and recorded by a medical doctor in the case report form corresponding to each volunteer.

**Collection of blood samples**

After an overnight fast lasting at least 10 h, blood samples were collected from the volunteers at the beginning of the intervention (day 0), just before vaccination (day 14), and during follow-up (days 42 and 70), using Vacutainers (S-Monovette, Sarstedt, Germany) containing ethylenediaminetetraacetic acid.

**Haemagglutination inhibition (HAI) test**

The reagents for the HAI test were from a World Health Organization Influenza Reagent Kit (Geneva, Switzerland). The influenza antigens contained in the kit are suitable for the serological diagnosis of influenza A(H1), A(H3), and B infections. The HAI tests were performed using standard procedures with chicken red blood cells according to the manual published by the WHO [21].

**Total immunoglobulin and cytokine measurements**

The total IgA and IgG concentrations in the plasma were measured in duplicates with enzyme-linked immunosorbent assay (ELISA) quantification kits, according to the manufacturer's instructions (Bethyl, Montgomery, TX, USA).

The cytokine and interleukin concentrations in the plasma were measured in duplicates with ELISA quantitation kits, according to the manufacturer's instructions (Affymetrix eBioscience, San Diego, CA, USA).

**Statistical analysis**

For seroconversion, the odd ratios (ORs) and 95% confidence intervals (CI) were obtained to assess the effect of treatment. A logistic model was performed with adjustment for age and sex.

The occurrence of illness and symptoms and the consumption of analgesic and antibiotics were described using the incidence ratio (IR) and incidence rate ratio (IRR) with the 95% CI and p value for the IRR. A Poisson regression model was adjusted to the number of events by sex, age and seroconversion.

For the cytokine and immunoglobulin concentrations, data were obtained at each time point of the study [baseline, 2 weeks (just before vaccination), 6 and 10 weeks]. The descriptive analyses for the responses are shown as the mean and standard error. The 95% CI for the mean and the bivariate statistical test to evaluate differences at each time point were performed using bootstrap methods. Adjusted analysis regression models were applied for a fixed time, group and seroconversion effect. Because regression models require meeting the assumption of normality for the residuals, a log 10 transformation of the responses was performed for IgA and IgG.

A 5% significance level was considered for the statistical tests.

The statistical SPSS version 19 (for the descriptive and bivariate analyses) and R 3.1 (for the modelling data) software were used to perform the analyses.

**Results**

A total of 98 subjects were recruited from 5 elderly residence homes and they were randomly distributed into two groups: the control group and the probiotic group. Before completion of the 10-week intervention period, 6 volunteers in the control group and 9 in the probiotic group discontinued the intervention and dropped out of the study for the reasons detailed in the study flow chart (Fig. 1). Afterwards, one additional subject discontinued the study during the follow-up period in the control group. The reasons for drop out were similar in both groups. The most common reason was voluntary resignation, owing to refusal to have blood drawn. Finally, data from 84 volunteers were included for the analysis of immune responses, and data from 83 volunteers were included for the analysis of the incidence of symptoms of infection.

No significant differences were detected in the baseline characteristics of the volunteers (Table 1). Most of the volunteers, 68%, were older than 80 years, 28% were between 70 and 80 years old and 4% were between 65 and 69 years old.

The diets of the volunteers were recorded during the study period. No significant differences were noted in the diets of the volunteers among the study groups or between baseline and the end of the intervention (data not shown). Therefore, the significant effects observed for the outcomes cannot be attributed to the participants’ different dietary habits.
Influenza vaccination immune response

The antibody titres against the three viruses included in the vaccine were evaluated at baseline and at 4 weeks and 8 weeks after influenza vaccination. Seroconversion was defined as the proportion of vaccinated individuals who achieved a haemagglutination inhibition titre > 1:40 for at least one of the virus subtypes included in the vaccine. No significant differences were observed between the measurements taken at weeks 6 and 10 (4 and 8 weeks after vaccination) ($p = 0.519$). The percentage of responders was higher in the probiotic group than in the control group (93.1 and 72.7%, respectively). The odds of seroconversion for at least one of the antigens of the vaccine was 4.94 times higher in the probiotic group than in the control group ($p = 0.036$) (Table 2). Similar effects were observed when the definition of seroconversion was based on an at least four-fold increase of the haemagglutination inhibition (HAI) titre against the influenza virus over baseline (Table 2). No interaction of age or sex was detected ($p = 0.146$ and $p = 0.981$, respectively).

No significant differences were detected in the immunoglobulin A and G or the cytokine IL-4, IL-10 and TNF-alpha concentrations (Table 3).

Influenza-like illness and respiratory symptoms

The incidence of ILI was 46.3% lower in the probiotic group than in the control group, but the difference was not significant ($p = 0.194$). The incidences of symptoms usually associated with respiratory infections were lower in the probiotic group than in the control group, although the differences reached significance for only sore throat (Table 4). The incidence of local respiratory symptoms (sore throat, cough and/or nasal congestion) was approximately 48% lower in the probiotic group than in the control group ($p = 0.007$).

### Table 1: Baseline characteristics of the subjects of the study

|                        | Control group | Probiotic group | p value |
|------------------------|--------------|-----------------|--------|
| Age (years ± SD)       | 81.76 ± 7.2  | 83.79 ± 6.5     | 0.148  |
| Male/female (%)        | 35.3/64.7    | 32/68           | 0.724  |
| BMI (Kg/m², mean ± SD) | 26.3 ± 5.1   | 26.3 ± 3.5      | 0.974  |
| Current smoker (%)     | 6.7          | 0               | 0.110  |
| Previous smoking habits (%) | 13.3       | 21.1            | 0.321  |
| Years as smokers (mean ± SD) | 38.1 ± 13.1 | 27.5 ± 11.7     | 0.142  |

### Table 2: Seroconversion in subjects of the study

| Seroconversion                  | Control group (%) responders | Probiotic group (%) responders | Increase probiotic vs control (%) | OR adjusted 95% confidence interval (LL–UL) | p value |
|---------------------------------|------------------------------|-------------------------------|----------------------------------|-------------------------------------------|--------|
| Seroconversion (titre > 1:40)   | 72.7                         | 93.1                          | 28.1                             | 4.94                                      | 0.036  |
| Seroconversion (increase > 4 titers) | 75.0                      | 92.1                          | 22.8                             | 3.05                                      | 0.012  |

Statistically significant values ($p < 0.05$) are given in bold. 

© Springer
Logistic regression models were applied to obtain the adjusted estimates for the incidence ratios for each symptom in the seroconverted patients, but no significant interactions were found (p > 0.05).

The consumption of analgesic and antibiotic treatments was recorded during the study (Table 5). The administration of antibiotics was similar in both groups; however, the administration of analgesic treatments was 86% lower in the probiotic group (p = 0.008). A logistic model was applied to obtain the adjusted odds ratio (OR) for analgesic consumption by age and sex. No significant interactions of age or sex were detected (p = 0.316 and p = 0.929, respectively). The odds of analgesic consumption were significantly lower for the probiotic group (more than 6 times) than for the control group (OR = 0.151; 95% CI 0.022–0.641; p = 0.021).

**Gastrointestinal symptoms**

The incidence of gastrointestinal symptoms (nausea/vomiting or lack of appetite) was also evaluated. The incidence of these symptoms was lower in the probiotic group than in the control group (0.105 ± 0.39 vs 0.267 ± 0.84); however, the difference was not significant (p = 0.651).

**Discussion**

The elderly population is more susceptible to infectious diseases, owing to loss of the ability of the immune system to function [3, 4]. Vaccination is strongly recommended for this population because common infectious diseases, such as the flu, have a highly negative effect. However, the immune response defect provokes a lower level of protection after vaccination. Several strategies aimed at improving the response to vaccination in this population have been evaluated, including the use of probiotics. The present

---

**Table 3** Immunological parameters

|               | Control group |          |          |          | Probiotic group |          |          |
|---------------|---------------|----------|----------|----------|-----------------|----------|----------|
|               | Baseline      | 2 weeks  | 6 weeks  | 10 weeks | Baseline        | 2 weeks  | 6 weeks  | 10 weeks |
| Ig A (mg/dL)  | 3.65 ± 2.4    | 3.67 ± 2.4 | 3.91 ± 2.2 | 3.81 ± 2.2 | 4.22 ± 2.5     | 3.93 ± 2.1 | 4.13 ± 2.3 | 4.24 ± 2.3 |
| Ig G (mg/dL)  | 8.83 ± 6.9    | 9.16 ± 7.1 | 10.28 ± 7.6 | 9.91 ± 7.3 | 10.05 ± 7.9    | 10.42 ± 9.7 | 10.45 ± 8.1 | 11.08 ± 10.1 |
| IL-4 (pg/mL)  | 0.81 ± 0.5    | 0.79 ± 0.8 | 0.94 ± 0.5 | 0.83 ± 0.4 | 0.78 ± 0.5     | 0.80 ± 0.4 | 0.78 ± 0.4 | 0.71 ± 0.3 |
| IL-10 (pg/mL) | 1.92 ± 2.7    | 1.81 ± 2.4 | 2.47 ± 3.6 | 2.56 ± 3.4 | 3.02 ± 5.3     | 3.65 ± 8.4 | 3.47 ± 9.1 | 2.67 ± 5.1 |
| TNF-alpha (pg/mL) | 3.61 ± 6.0  | 3.52 ± 5.3 | 4.93 ± 6.5 | 5.11 ± 8.5 | 7.98 ± 12.7    | 5.30 ± 8.7 | 7.07 ± 9.3 | 7.61 ± 9.5 |

Data are showed as mean of concentration ± SD

---

**Table 4** Incidence of symptoms related to respiratory infections

|               | Cough | Nasal congestion | Sore throat | Headache | Muscle/bone pain | Fever | Tiredness | Local symptoms<sup>a</sup> | ILI<sup>b</sup> |
|---------------|-------|------------------|-------------|----------|-----------------|-------|-----------|-----------------------------|---------------|
| Control IR (SD) | 0.422 | 0.444            | 0.356       | 0.267    | 0.111           | 0.133 | 0.178     | 1.222                       | 0.244         |
| Probiotic IR (SD) | 0.289 | 0.237            | 0.105       | 0.080    | 0.105           | 0.132 | 0.079     | 0.632                       | 0.131         |
| IR decrease (%) | 31.5  | 46.6             | 70.5        | 70.0     | 5.4             | 0.75  | 55.6      | 48.3                        | 46.3          |
| p value       | 0.319 | 0.117            | **0.029**   | **0.059**| 0.934           | 0.982 | 0.231     | **0.007**                   | 0.194         |

Statistically significant values (p < 0.05) are given in bold

<sup>a</sup> Incidence of local respiratory symptoms (sore throat, cough and/or nasal congestion)

<sup>b</sup> ILI influenza-like illness

---

**Table 5** Pharmacological treatments related to symptoms of respiratory infections

|               | Antibiotic | Analgesic |
|---------------|------------|-----------|
| Control IR (SD) | 0.200 (0.40) | 0.378 (0.81) |
| Probiotic IR (SD) | 0.316 (0.57) | 0.053 (0.23) |
| Incidence rate decrease (%) | − 58       | 86.0      |
| p value       | 0.300      | **0.008** |

Statistically significant values (p < 0.05) are given in bold
study demonstrates that administration of Lc K8 significantly increases the percentage of responders to the vaccine. Despite the higher percentage of responders to the vaccine in the probiotic group, significant differences in the incidence of flu were not detected between groups. However, the diagnosis of flu was based on a confluence of symptoms rather than viral detection.

Interestingly, when the symptoms associated with respiratory infections were analysed, we observed a significant decrease in the incidence of symptoms, especially those related to upper respiratory infections. The effects of probiotics on upper respiratory infections have been previously reported for other strains. A Cochrane meta-analysis of 10 clinical trials involving a total of 3451 infants, children and adults has found that probiotics are more beneficial than placebo in terms of infection prevention [7]. Moreover, probiotics decrease the rate of acute upper respiratory tract infections and frequency of antibiotic use but also decrease of the duration of each single episode have been reported [7, 11].

Most studies include long intervention periods (months), and the incidence of respiratory infections is analysed during the intervention period [7, 22]. The coryniformis study is notable in that the intervention period was short (2 weeks), and the incidence of symptoms associated with respiratory infections was evaluated for 5 months after the probiotic intervention. Therefore, the effect of Lc K8 is not limited to the period of probiotic administration but is maintained over time. The permanence of the effect after treatment is discontinued which might have been due to the improved antibody response to the influenza-induced probiotic strain in response to influenza vaccination. However, most respiratory infections were not related to flu events and were identified as a common cold, which would involve another type of virus not included in the vaccine. Therefore, non-specific activation of the immune system might be involved in the protection against respiratory infections. Another hypothesis that might explain the permanence of the effect is intestinal colonization by the probiotic strain, which would allow the strain to continue activating the immune system of individuals over time. Nevertheless, colonization of the intestine by probiotic bacteria is considered to be transient. Thus, this colonization is not expected to be maintained for months after the cessation of ingestion, although some authors have detected permanent colonization at a very low level [23, 24].

In the Lc K8 study, no effects have been detected on the plasma cytokine and total immunoglobulin concentrations after the probiotic intervention. A previous study performed with the same probiotic strain in a hepatitis A vaccination protocol in a healthy adult population, has shown an adjuvant effect of the L. coryniformis strain, as evidenced by an increase in the production of specific antibodies against the antigens present in the hepatitis vaccine [18]. In the Redondo study, no effects attributed to Lc K8 administration have been observed on the cytokine concentration in the blood, and only a slight increase has been observed in the proportion of memory T lymphocytes (CD3 + CD4 + CD45RO+). As previously mentioned, because the effect of Lc K8 is observed mainly on local respiratory symptoms usually associated with the common cold, the effect might have been due to a general effect on the immune system instead of a specific higher response against the flu vaccine. In fact, a higher innate response has been related to the administration of probiotic strains. The polymorphonuclear (PMN) cell phagocytic capacity and natural killer (NK) cell activity have been identified as key immune functions against infection. Research in the elderly has shown that low NK activity is associated with the development of infectious diseases; thus, strategies to reinforce this activity should improve the immune response in this population [25, 26]. Several studies have shown the effect of probiotic strains on NK activity, although the results in the elderly vary and are strain and study dependent [10, 27, 28]. A previous study performed in healthy adults with a combination of Lc K8 and a L. gasseri (CECT5714) strain has found an increase in the proportion of NK cells and the phagocytic activity of monocytes and PMN cells [15]. However, the effects cannot be attributed solely to the L. coryniformis strain because a combination of strains was used.

Therefore, although the immune response of the elderly population was improved by increasing specific antibodies against the flu vaccine, the mediators of this immune effect should be clarified in future studies.

Interestingly, in the Lc K8 study, the consumption of analgesics was significantly lower (86%) in the elderly group who received the probiotic strain than in the control group. This decrease was consistent with the decrease in the incidence of symptoms observed in the probiotic group. The lower analgesic consumption is relevant from two perspectives. First, adverse effects, such as gastrointestinal problems, are usually associated with analgesic consumption [29, 30]. Moreover, analgesics may be counterproductive for elderly people because of possible interactions with concomitant pharmacological treatments or their special medical conditions [31]. Second, the decrease in analgesic treatments would affect health expenditures derived from the care of the elderly population.

In conclusion, the administration of L. coryniformis K8 CECT5711 to the elderly population increases the immune response against the influenza vaccine and decreases symptoms associated with respiratory infections. Probiotic administration may be a natural and safe strategy to improve the efficacy of vaccines and to protect against common respiratory infections in susceptible populations.

Acknowledgements Authors wish to thank for their collaboration in the study to Llenalia García Fernández (SEPLIN, Soluciones
Estadísticas -Granada, Spain-) for the statistical analysis of the data. This project is financed by the Centre for the Development of Industrial Technology (CDTI) and co-financed by the European Union under the European Regional Development Fund (ERDF) (ITC-20151354).

Compliance with ethical standards

Conflict of interest JF, JAML, CR, and MO are workers of Biosearch Life, owner of the patent of Lactobacillus fermentum CECT5711.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. World Health Organization (2012) Vaccines against influenza WHO position paper—November 2012. Weekly Epidemiol Record 87:461–476
2. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA (2007) Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 7:658–666
3. Hernandez-Vargas EA, Wilk E, Canini L, Toapanta FR, Binder SC, Uvarovsky A, Ross TM, Guzmán CA, Perelson AS, Meyer-Hermann M (2014) Effects of aging on influenza virus infection dynamics. J Virol 88(8):4123–4131
4. Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM (1999) Immune response to influenza vaccination in a large healthy elderly population. Vaccine 17(1):82–94
5. Podda A (2001) The adventuated influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19:2673–2680
6. Hevia A, Delgado S, Sánchez B, Margolles A (2015) Molecular players involved in the interaction between beneficial bacteria and the immune system. Front Microbiol 6:1285
7. Hao Q, Dong BR, Wu T (2015) Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2:CD006895
8. Weizman Z, Asli G, Alsheikh A (2005) Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 115:5–9
9. Maldonado J, Cañañave F, Sempere L, Vela F, Sánchez AR, Narbona E, López-Huertas E, Geerlings A, Valero AD, Olives M et al (2012) Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections. Pediatr Gastroenterol Nutr 54:55–61
10. Shida K, Sato T, Iizuka R, Hoshi R, Watanabe O, Igarashi T, Miyazaki K, Nanno M, Ishikawa F (2017) Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers. Eur J Nutr 56(1):45–53
11. Jespersen L, Tarnow I, Eskesen D, Morberg CM, Michelsen B, Bügel S, Dragsted LO, Rijkers GT, Calder PC (2015) Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Clin Nutr 101(6):1188–1196
12. Olivares M, Díaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonollá J, Navas M, Rodríguez JM, Xaus J (2007) Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition 23(3):254–260
13. Boge T, Rémyigy M, Vaudaine S, Tanguy J, Bourdett-Sicard R, van der Werf S (2009) A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 27(41):5677–5684
14. Martín R, Olivares M, Marín ML, Xaus J, Fernández L, Rodríguez JM (2005) Characterization of a reuterin-producing Lactobacillus coryniformis strain isolated from an artisan goat’s milk cheese. J Food Microbiol 104:267–277
15. Olivares M, Díaz-Ropero MP, Gómez N, Sierra S, Lara-Villoslada F, Maldonado JA, Martín R, Rodríguez JM, Xaus J (2006) The consumption of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus casei CECT5711, boost the immune system of healthy adults. Int Microbiol 9:47–52
16. Lara-Villoslada F, Sierra S, Boza J, Xaus J, Olivares M (2007) Beneficial effects of consumption of a dairy product containing two probiotic strains, Lactobacillus casei CECT5711 and Lactobacillus gasseri CECT5714 in healthy children. Nutr Hosp 22(4):496–502
17. Martínez-Cañavate A, Sierra S, Lara-Villoslada F, Romero J, Maldonado J, Boza J, Xaus J, Olivares M (2009) A probiotic dairy product containing L. gasseri CECT574 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy. Pediatr Allergy Immunol 20(6):592–600
18. Redondo N, Nova E, Gheorghe A, Diaz LE, Hernandez A, Marcos A (2017) Evaluation of Lactobacillus casei CECT5711 strain as a coadjuvant in a vaccination process: a randomised clinical trial in healthy adults. Nutr Metabol 14:2–9
19. Influenza vaccination (2017) ECDC http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx. Accessed 16 May 2017
20. Influenza case definitions (2017) Stockholm: ECDC http://ecdc.europa.eu/en/healthtopics/influenza/surveillance/Pages/influenza_case_definitions.aspx. Accessed 16 May 2017
21. World Health Organization (WHO) (2011) Manual for the laboratory diagnosis and virological surveillance of influenza. http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf. Accessed Dec 2015
22. Van Puyenbroeck K, Hens N, Coenen S, Michiels B, Beunckens C, Molenberghs G, Van Royen P, Verhoeven V (2012) Efficacy of daily intake of Lactobacillus casei Shirata on respiratory symptoms and influenza vaccination immune response: a randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents. Am J Clin Nutr 95(5):1165–1171
23. Lee YK1, Ho PS, Low CS, Arvilommi H, Salminen S (2004) Permanently colonized by Lactobacillus casei is hindered by the low rate of cell division in mouse gut. Appl Environ Microbiol 70(2):670–674
24. Guimondé M, Sakata S, Kalliomäki M, Isolauri E, Benyo Y, Salminen S (2006) Effect of maternal consumption of Lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J Pediatr Gastroenterol Nutr 42:166–170
25. Hazeldine J, Lord JM (2013) The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev 12(4):1069–1078
26. Ogata K, An E, Shiots Y, Nakamura K, Luo S, Yokose N, Minami S, Dan K (2001) Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 124(3):392–397
27. Miller LE, Lehtoranta L, Lehtinen MJ (2017) The effect of Bifidobacterium animalis ssp. lactis HN019 on cellular immune function in healthy elderly subjects: systematic review and meta-analysis. Nutrients 9(3):191
28. Dong H, Rowland I, Thomas LV, Yaqoob P (2013) Immunomodulatory effects of a probiotic drink containing *Lactobacillus casei* Shirota in healthy older volunteers. Eur J Nutr 52(8):1853–1863

29. Rahme E1, Nedjar H, Bizzi A, Morin S (2007) Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther Nov 26(10):1387–1398

30. Doherty M, Hawkey C, Goulder M, Gibb I, Hill N, Aspley S, Reader S (2011) A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis 70(9):1534–1541

31. Pavlicević I, Kuzmanić M, Rumboldt M, Rumboldt Z (2008) Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol Fall 15(3):e372-382